Abbott Laboratories $ABT Stake Reduced by Danica Pension Livsforsikringsaktieselskab

Danica Pension Livsforsikringsaktieselskab cut its stake in Abbott Laboratories (NYSE:ABT) by 49.1% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 787,773 shares of the healthcare product maker’s stock after selling 760,517 shares during the period. Abbott Laboratories accounts for 1.5% of Danica Pension Livsforsikringsaktieselskab’s holdings, making the stock its 11th biggest holding. Danica Pension Livsforsikringsaktieselskab’s holdings in Abbott Laboratories were worth $80,881,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the company. J. Stern & Co. LLP increased its holdings in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares during the period. Norges Bank acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $2,938,892,000. Assenagon Asset Management S.A. boosted its position in shares of Abbott Laboratories by 303.0% during the first quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after buying an additional 3,330,368 shares during the period. Ninety One UK Ltd bought a new position in Abbott Laboratories in the 4th quarter worth approximately $336,815,000. Finally, Vanguard Group Inc. increased its position in Abbott Laboratories by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after acquiring an additional 2,402,408 shares during the period. Institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In related news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction on Monday, April 27th. The stock was bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The shares were bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $99.67 on Wednesday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $173.61 billion, a price-to-earnings ratio of 32.26, a P/E/G ratio of 2.03 and a beta of 0.61. The stock’s fifty day simple moving average is $90.58 and its 200-day simple moving average is $101.66.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The firm had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the prior year, the business earned $1.26 EPS. The business’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.51 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 81.55%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, July 7th. UBS Group reduced their target price on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a report on Monday, April 20th. Raymond James Financial dropped their price target on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Mizuho reduced their price objective on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Finally, Bank of America decreased their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $118.61.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.